Free Trial

Colgate-Palmolive (CL) Stock Forecast & Price Target

Colgate-Palmolive logo
$92.03 -0.89 (-0.96%)
(As of 12/20/2024 05:40 PM ET)

Colgate-Palmolive - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
9
Buy
12

Based on 22 Wall Street analysts who have issued ratings for Colgate-Palmolive in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 22 analysts, 1 has given a sell rating, 9 have given a hold rating, and 12 have given a buy rating for CL.

Consensus Price Target

$105.11
14.21% Upside
According to the 22 analysts' twelve-month price targets for Colgate-Palmolive, the average price target is $105.11. The highest price target for CL is $122.00, while the lowest price target for CL is $91.00. The average price target represents a forecasted upside of 14.21% from the current price of $92.03.
Get the Latest News and Ratings for CL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Colgate-Palmolive and its competitors.

Sign Up

CL Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$105.11$105.11$103.83$84.14
Forecasted Upside14.21% Upside10.75% Upside0.51% Upside7.19% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

CL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Colgate-Palmolive Stock vs. The Competition

TypeColgate-PalmoliveConsumer Staples CompaniesS&P 500
Consensus Rating Score
2.50
2.50
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside14.21% Upside46.16% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent CL News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/28/2024Wells Fargo & Company
3 of 5 stars
C. Carey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderweight ➝ Underweight$100.00 ➝ $92.00-4.42%
10/28/2024TD Cowen
5 of 5 stars
R. Moskow
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$115.00 ➝ $110.00+16.40%
10/28/2024Stifel Nicolaus
4 of 5 stars
 DowngradeBuy ➝ Hold$105.00 ➝ $101.00+5.64%
10/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$113.00 ➝ $114.00+14.87%
9/24/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$121.00+17.12%
9/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$107.00 ➝ $109.00+1.06%
9/4/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$119.00 ➝ $122.00+11.95%
8/1/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Lewis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/30/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$100.00 ➝ $103.00+3.00%
7/29/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$103.00 ➝ $111.00+10.46%
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$91.00 ➝ $96.00-4.61%
7/26/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Zamacona
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/26/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$103.00 ➝ $95.00-1.61%
7/18/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $106.00+6.91%
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$103.00 ➝ $112.00+15.00%
7/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$100.00 ➝ $110.00+13.26%
6/24/2024BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Grundy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$109.00+12.06%
5/15/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Graja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$97.00 ➝ $107.00+13.01%
4/29/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$88.00 ➝ $95.00+4.38%
3/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$93.00+7.50%
1/29/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$91.00+9.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:57 PM ET.


Should I Buy Colgate-Palmolive Stock? CL Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these Colgate-Palmolive pros and cons to contact@marketbeat.com.

Colgate-Palmolive
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Colgate-Palmolive:

  • Colgate-Palmolive has a strong market capitalization of $76.46 billion, indicating a robust financial position and stability in the consumer products sector.
  • The company recently announced a quarterly dividend of $0.50 per share, translating to an annualized dividend of $2.00 and a yield of 2.14%, which can provide a steady income stream for investors.
  • Current stock price is $93.58, which is near its 52-week low of $75.50, potentially offering a buying opportunity for investors looking for value.
  • Analysts have a positive outlook, with an average rating of "Moderate Buy" and a price target of $105.11, suggesting potential for price appreciation.
  • Colgate-Palmolive's diverse product range, including oral, personal, and home care products, positions it well to capture various market segments and consumer needs.

Colgate-Palmolive
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Colgate-Palmolive for these reasons:

  • The company has a high debt-to-equity ratio of 9.46, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Insider ownership is relatively low at 0.37%, which may suggest a lack of confidence from those who know the company best.
  • Recent downgrades from analysts, including a cut from "buy" to "hold" by Deutsche Bank, may indicate concerns about the company's growth prospects.
  • Colgate-Palmolive's quick ratio of 0.68 suggests potential liquidity issues, as it indicates that the company may not have enough short-term assets to cover its short-term liabilities.
  • With a P/E ratio of 26.58, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.

CL Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Colgate-Palmolive is $105.11, with a high forecast of $122.00 and a low forecast of $91.00.

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Colgate-Palmolive in the last year. There is currently 1 sell rating, 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CL shares.

According to analysts, Colgate-Palmolive's stock has a predicted upside of 14.21% based on their 12-month stock forecasts.

Over the previous 90 days, Colgate-Palmolive's stock had 1 downgrade by analysts.

Colgate-Palmolive has been rated by research analysts at JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, TD Cowen, and Wells Fargo & Company in the past 90 days.

Analysts like Colgate-Palmolive more than other "consumer staples" companies. The consensus rating for Colgate-Palmolive is Moderate Buy while the average consensus rating for "consumer staples" companies is Hold. Learn more on how CL compares to other companies.


This page (NYSE:CL) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners